Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
First Claim
Patent Images
1. A method of treating loss of cognitive function caused by Alzheimer'"'"'s disease or Mild Cognitive Impairment in a patient that is ApoE4(−
- ), the method comprising;
orally administering a dosage unit of medium chain triglyceride to said patient in need thereof such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.1 to 50 mM causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function,wherein the dosage unit is given in a single dose.
1 Assignment
0 Petitions
Accused Products
Abstract
Methods and compositions for treating or preventing, the occurrence of senile dementia of the Alzheimer'"'"'s type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of triglycerides or fatty acids with chain lengths between 5 and 12, to said patient at a level to produce an improvement in cognitive ability.
-
Citations
16 Claims
-
1. A method of treating loss of cognitive function caused by Alzheimer'"'"'s disease or Mild Cognitive Impairment in a patient that is ApoE4(−
- ), the method comprising;
orally administering a dosage unit of medium chain triglyceride to said patient in need thereof such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.1 to 50 mM causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function, wherein the dosage unit is given in a single dose. - View Dependent Claims (2, 3, 4, 5, 6)
- ), the method comprising;
-
7. A method of treating loss of cognitive function caused by Alzheimer'"'"'s disease or mild cognitive impairment in a patient that is ApoE4(−
- ), the method comprising;
orally administering a dosage unit of medium chain triglyceride to said patient in need thereof such that the blood level of D-beta-hydroxybutyrate in the patient is raised to about 0.2 to 20 mM causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function. - View Dependent Claims (8, 9, 10, 11)
- ), the method comprising;
-
12. A method of treating loss of cognitive function caused by reduced neuronal metabolism in a patient that is ApoE4(−
- ), the method comprising;
orally administering a dosage unit of medium chain triglyceride (MCT) to said patient in need thereof, wherein said MCT are administered at a dose of about 3.4 g per day to about 680 g per day causing hyperketonemia in the patient, wherein the patient has a diet wherein carbohydrate intake is not restricted, resulting in ketone bodies being utilized for energy in the brain to thereby treat loss of cognitive function, wherein the dosage unit is given in a single dose. - View Dependent Claims (13, 14, 15, 16)
- ), the method comprising;
Specification